1. Home
  2. WRAP vs MGNX Comparison

WRAP vs MGNX Comparison

Compare WRAP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wrap Technologies Inc.

WRAP

Wrap Technologies Inc.

HOLD

Current Price

$1.72

Market Cap

111.3M

Sector

Industrials

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.71

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRAP
MGNX
Founded
2016
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.3M
115.8M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
WRAP
MGNX
Price
$1.72
$1.71
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
371.5K
725.3K
Earning Date
02-21-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
77.78
N/A
EPS
N/A
N/A
Revenue
$4,507,000.00
$149,962,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
155.26
52 Week Low
$1.20
$0.99
52 Week High
$3.23
$2.78

Technical Indicators

Market Signals
Indicator
WRAP
MGNX
Relative Strength Index (RSI) 38.38 47.47
Support Level $1.68 $1.68
Resistance Level $1.84 $1.74
Average True Range (ATR) 0.16 0.08
MACD -0.00 -0.01
Stochastic Oscillator 24.47 24.39

Price Performance

Historical Comparison
WRAP
MGNX

About WRAP Wrap Technologies Inc.

Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: